An interventional study of Pacing in Calcium Release Deficiency Syndrome (CRDS), sponsored by Population Health Research Institute. Recruiting at 21 sites in 7 countries. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Population Health Research Institute · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Arrhythmias, Cardiac with a site in Canada — 13 open to participants now, 15 under way, none of them phase 3. Arrhythmias, Cardiac · Canada.
Among the 73 studies in Arrhythmias, Cardiac with a site in Canada, this one is the 16th largest by planned enrollment of the 49 interventional ones that give a count, is one of 5 that started in 2023, is one of 25 with no phase, reaches primary completion later than 11 of the 14 other live ones, and was the 69th registered.
1,052 studies on the registry are indexed under Arrhythmias, Cardiac; 236 are open to participants now.
Browse Arrhythmias, Cardiac studies →13 of the 73 studies in Arrhythmias, Cardiac with a site in Canada are open now. Recruiting first, the newest first:
Cardurion Pharmaceuticals, Inc. · Sites in Canada, United States, France and 3 more countries
Ages 18–99
Novartis Pharmaceuticals · Sites in Canada, United States, China and 4 more countries
Ages 18+
Hamilton Health Sciences Corporation · Sites in Canada
Ages 18+
Myant Medical Corp. · Sites in Canada
Ages 18+
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18–80 · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 167 Arrhythmias, Cardiac studies recruiting now, 119 (71%) set no upper age limit and 13 (8%) stop at 75 or younger; 31 take children under 18; 26 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 13 · Phase 4 3
First in 1983; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 100 across 518 interventional studies indexed under Arrhythmias, Cardiac.
Median enrollment 240 across the 49 interventional studies, 172 across the 24 observational. Of the 53 that completed or were terminated, 13 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 73 have an industry lead sponsor. The 10 most frequent:
Population Health Research Institute is the lead sponsor of 115 studies on the registry; 26 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Population Health Research Institute has 5 studies filed under Arrhythmias, Cardiac — fewer than ten, so there is no comparison to draw.
9 of the studies in Arrhythmias, Cardiac with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT05258422McGill University Health Centre/Research Institute of the McGill University Health CentreStereotactic Arrhythmia Radioablation for Ventricular Tachycardia (StAR-VT) | 2026-12-31 |
| NCT06164808HelpWear Inc.Cardiac Arrhythmia Telemetry; Conventional vs HeartWatch | 2026-12-31 |
| NCT06174220Hamilton Health Sciences CorporationTargeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy | 2027-02-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 73 studies in Arrhythmias, Cardiac with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Calcium Release Deficiency Syndrome (CRDS) is a novel inherited arrhythmia syndrome secondary to RyR2 loss-of-function that confers a risk of sudden cardiac death. Diagnosis of CRDS presently requires cellular-based in vitro confirmation that an RyR2 variant causes loss-of-function. We hypothesize that CRDS can be diagnosed clinically through evaluation of the repolarization response to brief tachycardia, mediated by cardiac pacing, and a subsequent pause.
RyR2 loss-of-function variants have recently been established as causative for a new disease termed calcium release deficiency syndrome (CRDS) that confers a risk of malignant ventricular arrhythmias and sudden cardiac death. RyR2 encodes the cardiac ryanodine receptor, the calcium release channel on the sarcoplasmic reticulum that mediates excitation-contraction coupling through calcium-induced calcium-release. In contrast to CRDS, pathogenic RyR2 gain-of-function variants result in an autosomal dominant form of catecholaminergic polymorphic ventricular tachycardia (CPVT). The adrenergic-mediated ventricular arrhythmias characteristic of CPVT can be readily reproduced on exercise stress testing (EST), making EST the standard clinical diagnostic tool for CPVT.
In contrast to CPVT, the CRDS clinical phenotype is concealed with standard cardiac testing tools and its diagnosis presently requires cellular-based in vitro confirmation that an RyR2 variant causes loss-of-function. Beyond the significant time delay associated with in vitro functional analysis, this testing requires specialized expertise that is not widely available and remains research-based, making it impractical for routine use in clinical care. In this overall context, it is likely that the vast majority of global CRDS cases have yet to be diagnosed.
A prior report of an "atypical CPVT" family carrying an RyR2-p.M4109R variant observed marked and transient repolarization changes following pacing mediated tachycardia and a subsequent pause. Since publication of this report, in vitro characterization of the RyR2-p.M4109R variant has confirmed its being loss-of-function and the familial diagnosis has been revised to CRDS. Driven by these observations and promising preliminary findings, the DIAGNOSE CRDS study seeks to further investigate this apparent electrocardiographic signature of CRDS following brief tachycardia and subsequent pause as a potential method to clinically diagnose the condition.
Cohort 1: Calcium Release Deficiency Syndrome (CRDS) Cases
Inclusion criteria:
Exclusion criteria:
Cohort 2: Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Cases
Inclusion criteria:
Exclusion criteria:
Cohort 3: Survivors of Unexplained Cardiac Arrest (UCA)
Inclusion criteria:
Exclusion criteria:
Use of a QT prolonging medication at the time of the burst pacing maneuvers
Cohort 4: SVT controls
Inclusion criteria:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Separate ventricular and atrial pacing trains will be administered at different cycle lengths and the ventricular repolarization response on the first sinus beat following the subsequent pause will be evaluated.
Diagnostic Test: Pacing
1. Ventricular 10 beat burst at 500ms (120bpm) 2. Ventricular 10 beat burst at 400ms (150bpm) 3. Atrial 10 beat burst at 500ms (120bpm) 4. Atrial 10 beat burst at 400ms (150bpm).
ΔT-wave amplitude value
T-wave amplitude on first post-pause sinus beat subtracted by the T-wave amplitude on the last sinus beat prior to pacing
Time frame: At time of pacing maneuver
ΔQT value
Absolute QT value on first post-pause sinus beat subtracted by the absolute QT value on the last sinus beat prior to pacing
Time frame: At time of pacing maneuver
Absolute QT value
Absolute QT value on first post-pause sinus beat
Time frame: At time of pacing maneuver
Absolute T-wave amplitude
Absolute T-wave amplitude on first post-pause sinus beat
Time frame: At time of pacing maneuver
Plan to share: No
Started Feb 2023 (actual). Primary completion is estimated for Dec 2027, 58 months after the start.
Of 172 non-industry interventional studies with no phase under Arrhythmias, Cardiac, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 43. This study's planned 58 months is above that.
Counting every sponsor, half of 243 studies reached it within 24 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Population Health Research Institute →